In a blow to Eli Lilly, Novo Nordisk lands FDA OK for their next big entry in the diabetes market: Ozempic
An energized FDA has come through with an approval of Novo Nordisk’s once-weekly GLP-1 diabetes drug semaglutide, opening the door to a market many analysts are convinced is worth more than $2 billion a year in peak sales. And it could spell big trouble for rival Eli Lilly.
Type 2 diabetes is a massive and fast-growing disease, with a global market that has rewarded a handful of key players like Novo Nordisk a multibillion-dollar market. And Novo ran a typically thorough Phase III program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
